Anebulo Pharmaceuticals, Inc. ( (ANEB) ) has released its Q3 earnings. Here is a breakdown of the information Anebulo Pharmaceuticals, Inc. presented to its investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Anebulo Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company focused on developing treatments for cannabis-induced toxicity, with a lead product candidate called selonabant. In its latest earnings report for the third quarter of fiscal year 2025, Anebulo Pharmaceuticals highlighted its strategic focus on developing an intravenous formulation of selonabant for pediatric patients suffering from cannabis-induced central nervous system depression. The company plans to initiate a Phase 1 single ascending dose study of intravenous selonabant in healthy adults in the third quarter of 2025, addressing a significant unmet medical need for an emergency antidote to acute cannabis-induced toxicity, particularly in children.
Financially, Anebulo reported operating expenses of $1.9 million for the third quarter of fiscal 2025, slightly up from $1.7 million in the same period of fiscal 2024. The net loss for the quarter was $1.7 million, consistent with the previous year’s third quarter, but the loss per share improved to $(0.04) from $(0.06) due to an increase in the number of shares outstanding. The company’s cash and cash equivalents stood at $13.3 million as of March 31, 2025, with access to an additional $3 million through a loan agreement.
The company’s lead product, selonabant, is a CB1 receptor antagonist designed to counteract the effects of acute cannabis-induced toxicity. Anebulo has completed a Phase 2 clinical trial demonstrating the efficacy of oral selonabant in reversing the negative effects of THC in adults. The company is now prioritizing the development of an intravenous formulation for pediatric use, which could potentially expedite the approval process compared to the adult oral product.
Looking ahead, Anebulo Pharmaceuticals remains focused on advancing the development of selonabant, with plans to collaborate closely with regulatory authorities to address the unmet need for pediatric cannabis toxicity treatments. The company aims to leverage its clinical findings to bring a targeted therapy to market that could rapidly reverse the serious consequences of cannabis-induced toxicity in children.